Shutting Off an On Switch: Novel drugs slow two cancers in mice

One way to arrest cancer is to identify a molecule that malignant cells just can’t do without—and then disable it. Researchers now report success with two experimental drugs that target such a protein, which triggers rapid growth and other malignant changes in cancer cells.

In mice, one of the drugs slows multiple myeloma, a lethal bone marrow cancer, and the other limits fibrosarcoma, a tumor of fibrous tissues. The scientists report their findings in two articles in an upcoming Cancer Cell.

The researchers homed in on the protein called insulinlike growth factor-1 receptor (IGF-1R). Recent studies have linked excess IGF-1R to heightened risks of colon, prostate, breast, lung, and bladder cancers. Although IGF-1R shows up on the surface of healthy cells, it’s more common on tumor cells.

When bound by its natural partner, insulinlike growth factor, the receptor triggers far-reaching processes within a cell that spur growth and disrupt self-destruction signals. Such activation of IGF-1R boosts healthy growth of normal cells but may also make malignant ones proliferate unchecked.

Earlier studies also indicated that cancerous cells respond to IGF-1R activation by spurring development of new blood vessels that nourish a growing tumor, says Andrew L. Kung of the Dana-Farber Cancer Institute and Harvard Medical School in Boston. Test-tube studies showed that inhibiting IGF-1R reverses cells’ malignant behavior.

To test whether IGF-1R inhibitors might stop cancer, Kung and his colleagues first injected mice with human multiple myeloma cells. After 3 weeks, the researchers began injecting some of the animals with twice-daily doses of an IGF-1R inhibitor called NVP-ADW742, while other mice got inert shots. After 19 days of this treatment, mice getting the inhibitor had smaller tumors; they also outlived their counterparts.

In the other study, researchers in Switzerland implanted fibrosarcoma tumors under the skin of mice. One week after implantation, one group of mice received twice-daily oral doses of an IGF-1R inhibitor called NVP-AEW541, while another group got an inert substance. Eleven days after the start of treatment, mice getting the drug had tumors about one-third the size of those in the mice receiving the placebo, says Francesco Hofmann, a biochemist at Novartis Pharma AG in Basel, Switzerland. The company developed the two IGF-1R inhibitors, and Hofmann was a coauthor of both reports.

The inhibitors disable a portion of IGF-1R that acts as an enzyme within cells, says Derek LeRoith, chief of the Diabetes Branch at the National Institutes of Health in Bethesda, Md. Researchers who took a similar approach to disrupting enzyme signals in tumor cells, he says, developed the anti-leukemia drug imatinib mesylate, also called Gleevec.

IGF-1R inhibitors don’t appear to eradicate cancer. But Kung and his colleagues have shown in lab-dish experiments that IGF-1R suppression works even against cancer cells that are resistant to conventional chemotherapy.

Use up and down arrow keys to explore.Use right arrow key to move into the list.Use left arrow key to move back to the parent list.Use tab key to enter the current list item.Use escape to exit the menu.Use the Shift key with the Tab key to tab back to the search input.